Visual hallucinations in Parkinson's disease: Theoretical models

Movement Disorders

Volumn 29, Issue 13, 2014, Pages 1591-1598

  Muller, Alana J ^a   Shine, James M ^a   Halliday, Glenda M ^b   Lewis, Simon J G ^a  

^a UNIVERSITY OF SYDNEY   (Australia)

^b UNIVERSITY OF NEW SOUTH WALES   (Australia)

Author keywords

Parkinson's disease; Visual hallucinations; Visual misperceptions

Indexed keywords

COMPLICATION; HALLUCINATIONS; HUMAN; PARKINSON DISEASE; THEORETICAL MODEL;

HALLUCINATIONS; HUMANS; MODELS, THEORETICAL; PARKINSON DISEASE;

EID: 84911124769     PISSN: 08853185     EISSN: 15318257     Source Type: Journal    
DOI: 10.1002/mds.26004     Document Type: Review

References (74)

1. Forsaa EB, Larsen J, Wentzel-Larsen T, et al. A 12-year population-based study of psychosis in parkinson disease. Arch Neurol 2010;67:996-1001.
2. Goetz CG, Ouyang B, Negron A, Stebbins GT. Hallucinations and sleep disorders in PD: Ten-year prospective longitudinal study. Neurology 2010;75:1773-1779.
3. Grossi D, Trojano L, Pellecchia MT, Amboni M, Fragassi NA, Barone P. Frontal dysfunction contributes to the genesis of hallucinations in non-demented Parkinsonian patients. Int J Geriatr Psychiatry 2005;20:668-673.
4. Aarsland D, Brønnick K, Ehrt U, et al. Neuropsychiatric symptoms in patients with Parkinson's disease and dementia: frequency, profile and associated care giver stress. J Neurol Neurosurg Psychiatry 2007;78:36-42.
5. Factor S, Feustel P, Friedman J, et al. Longitudinal outcome of Parkinson's disease patients with psychosis. Neurology 2003;60:1756-1761.
6. Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J Neurol Neurosurg Psychiatry 2001;70:727-733.
7. Fénelon G, Mahieux F, Huon R, Ziégler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 2000;123:733-745.
8. Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of "benign hallucinations" in Parkinson disease. Arch Neurol 2006;63:713-716.
9. Grillner S, Kozlov A, Kotaleski JH. Integrative neuroscience: linking levels of analyses. Curr Opin Neurobiol 2005;15:614-621.
10. Silberberg G, Grillner S, LeBeau FE, Maex R, Markram H. Synaptic pathways in neural microcircuits. Trends Neurosci 2005;28:541-551.
11. Van Regenmortel MH. Reductionism and complexity in molecular biology. EMBO Rep 2004;5:1016-1020.
12. Manni R, Pacchetti C, Terzaghi M, Sartori I, Mancini F, Nappi G. Hallucinations and sleep-wake cycle in PD A 24-hour continuous polysomnographic study. Neurology 2002;59:1979-1981.
13. Arnulf I, Bonnet A-M, Damier P, et al. Hallucinations, REM sleep, and Parkinson's disease: a medical hypothesis. Neurology 2000;55:281-288.
14. Lee AH, Weintraub D. Psychosis in Parkinson's disease without dementia: common and comorbid with other non-motor symptoms. Mov Disord 2012;27:858-863.
15. Manni R, Terzaghi M, Ratti P-L, Repetto A, Zangaglia R, Pacchetti C. Hallucinations and REM sleep behaviour disorder in Parkinson's disease: dream imagery intrusions and other hypotheses. Consciousness and Cognition 2011;20:1021-1026.
16. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 2001;57:2078-2082.
17. Nardone R, Bergmann J, Brigo F, et al. Functional evaluation of central cholinergic circuits in patients with Parkinson's disease and REM sleep behavior disorder: a TMS study. J Neural Transm 2013;120:413-422.
18. Manganelli F, Vitale C, Santangelo G, et al. Functional involvement of central cholinergic circuits and visual hallucinations in Parkinson's disease. Brain 2009;132:2350-2355.
19. Janzen J, 'T Ent D, Lemstra AW, Berendse HW, Barkhof F, Foncke EMJ. The pedunculopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study. J Neurol 2012;259:147-154.
20. Shin S, Lee JE, Hong JY, Sunwoo M-K, Sohn YH, Lee PH. Neuroanatomical substrates of visual hallucinations in patients with non-demented Parkinson's disease. J Neurol Neurosurg Psychiatry 2012;83:1155-1161.
21. Zahodne LB, Fernandez HH. Pathophysiology and treatment of psychosis in Parkinson's disease. Drugs Aging 2008;25:665-682.
22. Meltzer HY, Mills R, Revell S, et al. Pimavanserin, a serotonin2A receptor inverse agonist, for the treatment of Parkinson's disease psychosis. Neuropsychopharmacology 2010;35:881-892.
23. Miyasaki J, Shannon K, Voon V, et al. Practice parameter: evaluation and treatment of depression, psychosis, and dementia in Parkinson disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology. Neurology 2006;66:996-1002.
24. Goetz CG, Vaughan CL, Goldman JG, Stebbins GT. I finally see what you see: Parkinson's disease visual hallucinations captured with functional neuroimaging. Mov Disord 2014;29:115-117.
25. Ibarretxe-Bilbao N, Ramirez-Ruiz B, Junque C, et al. Differential progression of brain atrophy in Parkinson's disease with and without visual hallucinations. J Neurol Neurosurg Psychiatry 2010;81:650-657.
26. Ramírez-Ruiz B, Martí MJ, Tolosa E, et al. Cerebral atrophy in Parkinson's disease patients with visual hallucinations. Eur J Neurol 2007;14:750-756.
27. Solms M. Dreaming and REM sleep are controlled by different brain mechanisms. Behav Brain Sci 2000;23:843-850.
28. Harding AJ, Stimson E, Henderson JM, Halliday GM. Clinical correlates of selective pathology in the amygdala of patients with Parkinson's disease. Brain 2002;125:2431-2445.
29. Harding A, Broe G, Halliday G. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 2002;125:391-403.
30. Gallagher DA, Parkkinen L, O'Sullivan SS, et al. Testing an aetiological model of visual hallucinations in Parkinson's disease. Brain 2011;134:3299-3309.
31. Lewis SJ, Shine JM, Duffy S, Halliday G, Naismith SL. Anterior cingulate integrity: executive and neuropsychiatric features in Parkinson's disease. Mov Disord 2012;27:1262-1267.
32. Boecker H, Ceballos-Baumann AO, Volk D, Conrad B, Forstl H, Haussermann P. Metabolic alterations in patients with Parkinson disease and visual hallucinations. Arch Neurol 2007;64:984-988.
33. Pacchetti C, Manni R, Zangaglia R, et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov Disord 2005;20:1439-1448.
34. Collerton D, Perry E. Dreaming and hallucinations-continuity or discontinuity? Perspectives from dementia with Lewy bodies. Conscious Cogn 2011;20:1016-1020.
35. Diederich NJ, Fenelon G, Stebbins G, Goetz CG. Hallucinations in Parkinson disease. Nat Rev Neurol 2009;5:331-342.
36. Collerton D, Perry E, McKeith I. Why people see things that are not there: a novel perception and attention deficit model for recurrent complex visual hallucinations. Behav Brain Sci 2005;28:737-757.
37. Barnes J, Boubert L, Harris J, Lee A, David AS. Reality monitoring and visual hallucinations in Parkinson's disease. Neuropsychologia 2003;41:565-574.
38. Collignon O, Van der Linden M, Larøi F. Source monitoring for actions in hallucination proneness. Cogn Neuropsychiatry 2005;10:105-123.
39. Johnson MK. Source monitoring and memory distortion. Philosophical Transactions of the Royal Society of London Series B: Biological Sciences 1997;352:1733-1745.
40. Mitchell KJ, Johnson MK. Source monitoring 15 years later: what have we learned from fMRI about the neural mechanisms of source memory? Psychol Bull 2009;135:638.
41. Buda M, Fornito A, Bergström ZM, Simons JS. A specific brain structural basis for individual differences in reality monitoring. J Neurosci 2011;31:14308-14313.
42. Sanchez-Castaneda C, Rene R, Ramirez-Ruiz B, et al. Frontal and associative visual areas related to visual hallucinations in dementia with Lewy bodies and Parkinson's disease with dementia. Mov Disord 2010;25:615-622.
43. Ramírez-Ruiz B, Martí MJ, Tolosa E, et al. Brain response to complex visual stimuli in Parkinson's patients with hallucinations: a functional magnetic resonance imaging study. Mov Disord 2008;23:2335-2343.
44. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov Disord 2005;20:130-140.
45. Hobson JA, Pace-Schott EF, Stickgold R. Dreaming and the brain: toward a cognitive neuroscience of conscious states. Behav Brain Sci 2000;23:793-842.
46. Datta S. Cellular basis of pontine ponto-geniculo-occipital wave generation and modulation. Cell Mol Neurobiol 1997;17:341-365.
47. Datta S. Cellular and chemical neuroscience of mammalian sleep. Sleep Med 2010;11:431-440.
48. Price MJ, Feldman RG, Adelberg D, Kayne H. Abnormalities in color vision and contrast sensitivity in Parkinson's disease. Neurology 1992;42:887-887.
49. Oh YS, Kim JS, Chung SW, et al. Color vision in Parkinson's disease and essential tremor. Eur J Neurol 2011;18:577-583.
50. Pieri V, Diederich N, Raman R, Goetz C. Decreased color discrimination and contrast sensitivity in Parkinson's disease. J Neurol Sci 2000;172:7-11.
51. Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin Neuropharmacol 1998;21:289-295.
52. Matsui H, Udaka F, Tamura A, et al. Impaired visual acuity as a risk factor for visual hallucinations in Parkinson's disease. J Geriatr Psychiatry Neurol 2006;19:36-40.
53. Goetz CG, Fan W, Leurgans S. Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: positive impact on long-term worsening. Mov Disord 2008;23:1541-1545.
54. Tagai K, Nagata T, Shinagawa S, Tsuno N, Ozone M, Nakayama K. Mirtazapine improves visual hallucinations in Parkinson's disease: a case report. Psychogeriatrics 2013;13:103-107.
55. Bronnick K, Emre M, Tekin S, Haugen SB, Aarsland D. Cognitive correlates of visual hallucinations in dementia associated with Parkinson's disease. Mov Disord 2011;26:824-829.
56. Imamura K, Wada-Isoe K, Kitayama M, Nakashima K. Executive dysfunction in non-demented Parkinson's disease patients with hallucinations. Acta Neurol Scand 2008;117:255-259.
57. Koerts J, Borg MA, Meppelink AM, Leenders KL, van Beilen M, van Laar T. Attentional and perceptual impairments in Parkinson's disease with visual hallucinations. Parkinsonism Relat Disord 2010;16:270-274.
58. Spreng RN, Grady CL. Patterns of brain activity supporting autobiographical memory, prospection, and theory of mind, and their relationship to the default mode network. J Cogn Neurosci 2010;22:1112-1123.
59. Shine JM, Halliday GM, Naismith SL, Lewis SJG. Visual misperceptions and hallucinations in Parkinson's disease: dysfunction of attentional control networks? Mov Disord 2011;26:2154-2159.
60. Corbetta M, Shulman GL. Control of goal-directed and stimulus-driven attention in the brain. Nat Rev Neurosci 2002;3:201-215.
61. Binder JR, Frost JA, Hammeke TA, Bellgowan P, Rao SM, Cox RW. Conceptual processing during the conscious resting state: a functional MRI study. J Cogn Neurosci 1999;11:80-93.
62. Meppelink AM, Koerts J, Borg M, Leenders KL, van Laar T. Visual object recognition and attention in Parkinson's disease patients with visual hallucinations. Mov Disord 2008;23:1906-1912.
63. Asplund CL, Todd JJ, Snyder AP, Marois R. A central role for the lateral prefrontal cortex in goal-directed and stimulus-driven attention. Nat Neurosci 2010;13:507-512.
64. Goldman JG, Stebbins GT, Dinh V, Bernard B, Merkitch D, Goetz CG. Visuoperceptive region atrophy independent of cognitive status in patients with Parkinson's disease with hallucinations. Brain 2014:awt360.
65. Pizzi SD, Franciotti R, Tartaro A, et al. Structural alteration of the dorsal visual network in DLB patients with visual hallucinations: a cortical thickness MRI study. PloS One 2014;9:e86624.
66. Shine JM, Halliday GM, Gilat M, et al. The role of dysfunctional attentional control networks in visual misperceptions in Parkinson's disease. Hum Brain Mapp 2014;35:2206-2219.
67. Greicius MD, Krasnow B, Reiss AL, Menon V. Functional connectivity in the resting brain: a network analysis of the default mode hypothesis. Proc Natl Acad Sci 2003;100:253-258.
68. Shine JM, O'Callaghan C, Halliday GM, Lewis SJG. Tricks of the mind: visual hallucinations as disorders of attention. Prog Neurobiol 2014;116:58-65.
69. Roebroeck A, Formisano E, Goebel R. The identification of interacting networks in the brain using fMRI: Model selection, causality and deconvolution. NeuroImage 2011;58:296-302.
70. Fénelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology 2006;66:93-98.
71. Goetz C, Pappert E, Blasucci L, et al. Intravenous levodopa in hallucinating Parkinson's disease patients high-dose challenge does not precipitate hallucinations. Neurology 1998;50:515-517.
72. Novotny EJ, Fulbright RK, Pearl PL, Gibson KM, Rothman DL. Magnetic resonance spectroscopy of neurotransmitters in human brain. Ann Neurol 2003;54:S25-S31.
73. Stam CJ, Reijneveld JC. Graph theoretical analysis of complex networks in the brain. Nonlinear Biomedical Physics 2007;1:3.
74. Reijneveld JC, Ponten SC, Berendse HW, Stam CJ. The application of graph theoretical analysis to complex networks in the brain. Clin Neurophysiol 2007;118:2317-2331.